Skip to main content

Table 1 Baseline characteristics of patients with effective ECV and ineffective ECV

From: Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study

 

Effective ECV (N = 1146)

Ineffective ECV (N = 852)

p

Age mean (median) years

64 (65)

63 (64)

0.01

Age > 75 years

176 (15.4)

117 (13.7)

0.06

Female

284 (24.8)

267 (31.3)

<0.01

First AF episode

528 (46.1)

397 (46.6)

0.82

Prior cardioversion

532 (46.4)

380 (44.6)

0.61

CHA2DS2-VASc-score ≥2

655 (57.2)

468 (54.9)

0.34

Duration of AF disease ≤1 year

527 (53.2)

374 (51.7)

0.56

Age of index AF episode

  > 180 daysa

76 (6.6)

65 (7.6)

0.60

  < 30 daysa

215 (18.8)

175 (20.5)

0.60

Ventricular rate (/min)

  < 60/min

45 (4.6)

17 (2.3)

0.01

 median

87 (30)

87 (30)

0.37

Left atrial diameter (mm)b

 median

46 (9)

46 (8)

0.40

Ejection fraction (%)c

 median

54 (17)

53 (17)

0.03

 Prior AF ablation

41 (3.6)

72 (8.5)

<0.01

 History of heart failure

173 (15.1)

150 (17.6)

0.14

 Hypertension

598 (52.2)

451 (52.9)

0.75

 History of CKD

59 (5.1)

54 (6.3)

0.28

 GFR <50 ml/mind

24 (4.1)

32 (7.1)

0.04

 Diabetes

171 (14.9)

115 (13.5)

0.40

 Prior stroke/TIA

76 (6.6)

55 (6.5)

0.93

 Coronary artery disease

179 (15.6)

115 (13.5)

0.20

 Pacemaker

105 (9.2)

82 (9.6)

0.76

Medication at discharge

 Beta blocker

946 (83.1)

720 (85.2)

0.22

 Digoxin

89 (7.8)

123 (14.6)

<0.01

 Verapamil

10 (0.9)

10 (1.2)

0.51

 Any antiarrhythmic agente

163 (14.3)

158 (18.8)

0.01

 Flecainide

67 (5.9)

44 (5.2)

0.55

 Amiodarone

65 (5.7)

79 (9.4)

0.01

  1. Values in parentheses are % or interquartile range, AF atrial fibrillation, CKD chronic kidney disease, ECV elective cardioversion, GFR glomerular filtration rate, TIA transient ischemic attack
  2. adata is missing in 834 (41.7%) cases
  3. bdata is missing in 1194 (59.8%) cases
  4. cdata is missing in 1142 (57.2%) cases
  5. ddata is missing in 955 (47.8%) cases
  6. eAntiarrhythmic agents comprised flecainide, amiodarone, propafenone, quinidine or disopyramide and dronedarone